Karyopharm Therapeutics Inc. (KPTI): Debt Offering News

KPTI – Commences $150 mln offering of convertible senior notes due 2025.


Key Facts Surrounding This News Item


  • KPTI had a POWR Rating of D (Sell) coming into today.
  • KPTI was -5.23% below its 10-Day Moving Average coming into today.
  • KPTI was -11.30% below its 20-Day Moving Average coming into today.
  • KPTI was -14.31% below its 50-Day Moving Average coming into today.
  • KPTI was -14.51% below its 100-Day Moving Average coming into today.
  • KPTI was -2.20% below its 200-Day Moving Average coming into today.
  • KPTI had returned +61.98% year-to-date leading up to today’s news, versus a +9.26% return from the benchmark S&P 500 during the same period.

More Info About Karyopharm Therapeutics Inc. (KPTI)


Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts. View our full KPTI ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

KPTI at a Glance

KPTI Current POWR Rating™
Overall POWR Rating™
KPTI Current Price $13.11 3.88%
More KPTI Ratings, Data, and News

KPTI Price Reaction

The day of this event (Oct. 9, 2018)
KPTI Closing Price$15.56 0.06%
KPTI Volume344,600
29.88% from avg
Leading up to this event
KPTI 1-mo returnN/A%
After this event
KPTI 1-day return25.05%
KPTI 3-day return23.41%
KPTI 5-day return18.61%

KPTI Price Chart



More Karyopharm Therapeutics Inc. (KPTI) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All KPTI News
Page generated in 0.8851 seconds.